ApprovalTrail

Approval · Notice of Compliance 21073 · 2018

CYSTADANE: Notice of Compliance 21073

Issued July 12, 2018

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
21073
Date
July 12, 2018
Company
Recordati Rare Diseases Canada IncToronto, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
Chages to specifications

Products in this notice

BrandDINStatus today
CYSTADANENot yet assigned—

Medicinal ingredients